Whilst we have previously shown that loss of an entire IFN gene set occurs in bone metastasis29 and that host IFNAR is required for effective anti-tumor immunity,26 this is the first report of a single IFN biomarker in the primary tumor that can predict risk of metastasis and reflects active IFN signaling and a TRM signature. The gene discussed is IFNAR1; the disease is neoplasm.